Pamoja Capital

Mindgram is a science-based platform and mobile application focused on comprehensive mental wellness. It aims to enhance productivity by addressing stress and burnout among employees. The platform provides daily personalized coaching, psychological support, and group workshops through chat or video calls. This enables users to develop valuable skills and effectively manage workplace challenges. By prioritizing mental well-being, Mindgram supports individuals in improving their overall performance and resilience in professional environments.

Mindgram is a science-based platform and mobile application focused on comprehensive mental wellness. It aims to enhance productivity by addressing stress and burnout among employees. The platform provides daily personalized coaching, psychological support, and group workshops through chat or video calls. This enables users to develop valuable skills and effectively manage workplace challenges. By prioritizing mental well-being, Mindgram supports individuals in improving their overall performance and resilience in professional environments.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression in organ transplant recipients. Its lead product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all long-term immunosuppression therapy within twelve months of their transplant. Additionally, the company's technology facilitates the safe administration of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, minimizing the risks associated with traditional methods. Founded in 1988 and based in Louisville, Kentucky, with an office in Wellesley, Massachusetts, Talaris Therapeutics has transitioned from its former name, Regenerex, Inc., in March 2019. The company is currently in the late stages of clinical development, also exploring applications for patients with severe autoimmune and immune-mediated disorders.

Vapogenix, Inc. is a clinical-stage company based in Houston, Texas, that specializes in developing non-narcotic analgesics aimed at treating localized pain. Founded in 2006, the company focuses on a range of products, including topical analgesics designed to alleviate pain from venipuncture, venous cannulation, and minor dermatological procedures. Vapogenix's innovative approach utilizes formulated volatile anesthetics, which differ from traditional volatile anesthetics that are used only as general anesthetics through inhalation. By targeting pain directly at its source, Vapogenix aims to enhance patient comfort, particularly in children undergoing medical procedures, while improving efficiency for healthcare providers.